Hetero Labs, Hungary’s Gedeon Richter to collaborate for Semaglutide
Hetero Labs and Gedeon Richter have signed a global partnership to develop and commercialize a generic version of the diabetes and weight-loss drug Semaglutide. The collaboration aims to leverage their respective market strengths to launch in the US and Europe by 2027.
Why it matters
This partnership increases competition in the high-demand GLP-1 drug market, potentially improving global access to affordable weight-loss and diabetes treatments.
Budapest-headquartered Gedeon Richter and Hyderabad-based Hetero Labs announced on Wednesday signing of a global collaboration agreement for the joint development, registration and commercialisation of Semaglutide injection.
The report is a straightforward business announcement regarding a corporate partnership.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in